Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA remains negative

Q4 FY2025 EBITDA was -$1.79M, compared with -$523.5 a year earlier. Trailing-twelve-month EBITDA was -$1.94K.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly EBITDA holds near -$1.79M or moves back toward the trailing-twelve-month quarterly average of -$484.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$1.79M— QoQ
Last fiscal yearDec 2025
-$2.51M-34.5% YoY
LTMDec 2024
-$1.94K— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-342020.3%——
1 year-34.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

USD · from the income statement

Latest · FY2025
(2.51M) USD
Year-over-year change
-34.5%

EBITDA vs competitors

How MENS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
MENS Competitors
EBITDA for MENS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M USD+154.3%—7.3%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024-$1.94K USD———
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M USD-372.0%—16.4%
CELCCelcuity Inc.LTM Jun 2026-$185.22M USD-36.6%——
CGONCG Oncology, Inc. Common stockLTM Sep 2026-$233.76M USD-54.9%—3791.2%
CNTACentessa Pharmaceuticals plcLTM Mar 2026-$260.55M USD-24.8%——
APGEApogee Therapeutics, Inc.LTM Jun 2026-$291.3M USD-23.0%——
XENEXenon Pharmaceuticals Inc.LTM Sep 2026-$434.65M USD-30.9%——
DYNDyne Therapeutics, Inc.LTM Jun 2026-$495.35M USD-20.6%——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-$503.35M USD-11.9%—75.2%
AAPGAscentage Pharma Group InternationalFY2025-CN¥1.1B CNY-360.8%—196.1%
Peer median (excluding MENS) —-27.9%—75.2%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue121K122K127K120K100K
Gross Profit(121K)(122K)(127K)(120K)(100K)
Gross Margin—————
Research & Development1.56M1.29M1.07M927K731K
Selling, General & Admin845K1.54M1.73M1.13M1.78M
Operating Expenses2.4M2.83M2.8M2.06M2.51M
Depreciation & Amortization122K123K127K120K100K
EBITDA(3.24M)(5.74M)(3.52M)(1.86M)(2.51M)
EBITDA Margin—————
Operating Income(2.4M)(2.83M)(2.8M)(2.06M)(2.61M)
Operating Margin—————
Interest Income6K5K56K7K610K
Interest Expense835K765K757K1.04M2.54M
Other Income / Expenses(1.79M)(3.8M)(1.6M)(963K)(2.06M)
Income Before Tax(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Net Margin—————
EPS (Basic)(0.06)(0.09)(0.06)(0.04)(0.06)
EPS (Diluted)(0.06)(0.09)(0.06)(0.04)(0.06)
Weighted Avg Shares76.03M76.03M76.03M76.03M73.01M
Weighted Avg Shares (Diluted)76.03M76.03M76.03M76.03M73.01M

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.